Boston Scientific shareholders elect all nine director nominees at 2023 annual meeting

The advisory vote on the frequency of future advisory votes to approve the compensation of the Company’s “Named Executive Officers.” One Year Two Years Three Years Abstain Broker Non-Votes 1,217,156,075 749,405 7,599,630 632,442 40,477,444 Based on the votes set forth above, the Company’s stockholders approved, on a non-binding, advisory basis, a frequency of One Year for the non-binding, advisory vote on the compensation of the Company’s “Named Executive Officers.” The Board considered these voting results and other factors, and determined that the Company will hold future advisory votes on its executive compensation on an annual basis.

All nine director nominees were elected to the Company’s Board of Directors (the “Board”) for a one-year term to hold office until the Company’s 2024 Annual Meeting of Stockholders and until their successors have been elected and qualified. Nominee For Against Abstain Broker Non-Votes Nelda J. Connors 1,193,844,995 31,804,972 487,585 40,477,444 Charles J. Dockendorff 1,150,969,582 74,573,819 594,151 40,477,444 Yoshiaki Fujimori 1,213,401,876 12,156,923 578,753 40,477,444 Edward J. Ludwig 1,179,968,074 45,599,337 570,141 40,477,444 Michael F. Mahoney 1,148,531,592 77,041,192 564,768 40,477,444 David J. Roux 1,182,485,636 43,072,351 579,565 40,477,444 John E. Sununu 1,052,908,443 172,703,257 525,852 40,477,444 David S. Wichmann 1,213,001,870 12,535,441 600,241 40,477,444 Ellen M. Zane 1,062,082,525 163,593,247 461,780 40,477,444

The advisory vote on the compensation for the Company’s “Named Executive Officers” as disclosed in the Company’s proxy statement for the Annual Meeting was approved. For Against Abstain Broker Non-Votes 1,134,910,823 90,354,176 872,553 40,477,444

The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year was ratified. For Against Abstain 1,178,709,166 87,499,383 406,447